文献速递糖尿病

血浆LRG1与2型糖尿病患者新发心力衰竭风险相关

Association of Plasma Leucine-Rich α-2 Glycoprotein 1, a Modulator of Transforming Growth Factor-β Signaling Pathway, With Incident Heart Failure in Individuals With Type 2 Diabetes.
PubMed 文献 · Diabetes Care · 2020-12-08

在1978例2型糖尿病患者中随访中位7.1年,发现血浆LRG1水平与心衰新发及心衰住院风险独立相关,且加入LRG1可改善风险判别能力。

要点

  • LRG1最高四分位者新发心衰风险较最低四分位增加5.99倍。
  • LRG1最高四分位者心衰住院风险较最低四分位增加10.44倍。
  • 将LRG1加入临床变量模型可小幅提升心衰风险判别能力。

核心结论

  • 血浆LRG1与2型糖尿病患者新发心衰和心衰住院风险相关,可能参与心衰发病过程。

研究设计与样本

  • 前瞻性队列研究,纳入1978例2型糖尿病患者,随访中位7.1年(四分位距6.1-7.6年)。

主要发现

  • 随访期间共发生191例新发心衰和119例心衰住院事件。
  • 校正多个已知心肾危险因素后,LRG1第3和第4四分位较第1四分位的新发心衰风险比分别为3.60(95%CI 1.63-7.99)和5.99(95%CI 2.21-16.20)。
  • LRG1第3和第4四分位较第1四分位的心衰住院风险比分别为5.88(95%CI 1.83-18.85)和10.44(95%CI 2.37-45.98)。
  • 自然对数转换的LRG1每增加1个标准差,校正后新发心衰风险比为1.78(95%CI 1.33-2.38),心衰住院风险比为1.92(95%CI 1.27-2.92)。
  • 将LRG1加入临床变量模型后,新发心衰的AUC从0.79提升至0.81(P=0.02),心衰住院的AUC从0.81提升至0.84(P=0.02)。

临床怎么用

  • LRG1可能作为2型糖尿病患者心衰风险分层的候选新型生物标志物,尚需进一步研究验证。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Leucine-rich α-2 glycoprotein 1 (LRG1) is a circulating protein potentially involved in several pathways related to pathogenesis of heart failure (HF). We aimed to study whether plasma LRG1 is associated with risks of incident HF and hospitalization attributable to HF (HHF) in individuals with type 2 diabetes. RESEARCH DESIGN AND METHODS: A total of 1,978 individuals with type 2 diabetes were followed for a median of 7.1 years (interquartile range 6.1-7.6). Association of LRG1 with HF was studied using cause-specific Cox regression models. RESULTS: In follow-up, 191 incident HF and 119 HHF events were identified. As compared with quartile 1, participants with LRG1 in quartiles 3 and 4 had 3.60-fold (95% CI 1.63-7.99) and 5.99-fold (95% CI 2.21-16.20) increased risk of incident HF and 5.88-fold (95% CI 1.83-18.85) and 10.44-fold (95% CI 2.37-45.98) increased risk of HHF, respectively, after adjustment for multiple known cardiorenal risk factors. As a continuous variable, 1 SD increment in natural log-transformed LRG1 was associated with 1.78-fold (95% CI 1.33-2.38) adjusted risk of incident HF and 1.92-fold (95% CI 1.27-2.92) adjusted risk of HHF. Adding LRG1 to the clinical variable-based model improved risk discrimination for incident HF (area under the curve [AUC] 0.79-0.81; P = 0.02) and HHF (AUC 0.81-0.84; P = 0.02). CONCLUSIONS: Plasma LRG1 is associated with risks of incident HF and HHF, suggesting that it may potentially be involved in pathogenesis of HF in individuals with type 2 diabetes. Additional studies are warranted to determine whether LRG1 is a novel biomarker for HF risk stratification.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Liu JJ, Pek SLT, Wang J, et al. Association of Plasma Leucine-Rich α-2 Glycoprotein 1, a Modulator of Transforming Growth Factor-β Signaling Pathway, With Incident Heart Failure in Individuals With Type 2 Diabetes. Diabetes Care. 2020. PMID: 33293346. doi:10.2337/dc20-2065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。